Thinking of joining a study?

Register your interest

Become a volunteer?

Clinical trials for Cancer in United States

6986 results

Sort By:

Hormone Therapy (Apalutamide) and Image-guided Stereotactic Body Radiation Therapy for the Treatment of Patients With Prostate Cancer, HEATWAVE Trial

Study ID: NCT06067269
Start Date: 2024-03-28
End Date: 2027-12-01
Study Type

Interventional

Study Phase

Phase2

No. of Participants

95

Intervention / Treatment

Apalutami

Biospecimen Collection

Computed Tomography

Gallium Ga 68 Gozetotide

Guided Stereotactic Body Radiation Therapy

Multiparametric Magnetic Resonance Imaging

Positron Emission Tomography

Administration Questionnaire

Sponsor

Jonsson Comprehensive Cancer Center

Source: clinicaltrials.gov

Share:
Add to list

Acalabrutinib and Obinutuzumab for the Treatment of Chronic Lymphocytic Leukemia

Study ID: NCT04505254
Start Date: 2020-08-25
End Date: 2027-06-30
Study Type

Interventional

Study Phase

Phase2

No. of Participants

60

Intervention / Treatment

Acalabrutinib

Obinutuzumab

Sponsor

M.D. Anderson Cancer Center

Source: clinicaltrials.gov

Share:
Add to list

Evaluating Microarray Pharmacogenetic Testing in Cancer Patients

Study ID: NCT06489041
Start Date: 2025-07-18
End Date: 2026-12
Study Type

Interventional

Study Phase

Not Applicable

No. of Participants

120

Intervention / Treatment

Pharmacogenomic Testing with the "Global Diversity Array with Enhanced PGx"

Sponsor

Wake Forest University Health Sciences

Source: clinicaltrials.gov

Share:
Add to list

Diffusion Basis Spectrum Imaging of the Prostate

Study ID: NCT04420702
Start Date: 2020-02-27
End Date: 2027-05-31
Study Type

Interventional

Study Phase

Not Applicable

No. of Participants

500

Intervention / Treatment

MRI with DBSI analysis

Sponsor

Washington University School of Medicine

Source: clinicaltrials.gov

Share:
Add to list

Expanded Access Protocol Using CD3+/CD19+ Depleted PBSC

Study ID: NCT02356653
Start Date: 2013-12
End Date: 2030-01
Study Type

Interventional

Study Phase

Early_phase1

No. of Participants

100

Intervention / Treatment

Transplant of stem cells with CD3+/CD19+ depletion (CliniMACs)

Sponsor

Children's Hospital of Philadelphia

Source: clinicaltrials.gov

Share:
Add to list

ADG126 in Combination With Pembrolizumab in Patients With Advanced/Metastatic Solid Tumors

Study ID: NCT05405595
Start Date: 2022-06-15
End Date: 2027-04-30
Study Type

Interventional

Study Phase

Phase2

No. of Participants

152

Intervention / Treatment

ADG126

Pembrolizumab (KEYTRUDA®)

Standard of Care (Trifluridine/Tipiracil-Bevacizumab)

Standard of care (Fruquintinib)

Sponsor

Adagene Inc

Source: clinicaltrials.gov

Share:
Add to list

A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma

Study ID: NCT06064877
Start Date: 2024-01-11
End Date: 2027-11
Study Type

Interventional

Study Phase

Phase3

No. of Participants

410

Intervention / Treatment

Ficlatuzumab

Cetuximab

Placebo

Sponsor

AVEO Pharmaceuticals, Inc.

Source: clinicaltrials.gov

Share:
Add to list

KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors

Study ID: NCT06026410
Start Date: 2023-10-18
End Date: 2027-04
Study Type

Interventional

Study Phase

Phase1

No. of Participants

270

Intervention / Treatment

Leverage

Cabozantinib

Higher dose

Sponsor

Kura Oncology, Inc.

Source: clinicaltrials.gov

Share:
Add to list

[18F]FES PET/.CT in Uterine Cancer

Study ID: NCT05916196
Start Date: 2024-04-05
End Date: 2027-08-01
Study Type

Interventional

Study Phase

Phase2

No. of Participants

30

Intervention / Treatment

18F-Fluoroestradiol

Sponsor

Abramson Cancer Center at Penn Medicine

Source: clinicaltrials.gov

Share:
Add to list

This is a Study to Evaluate the Safety and Tolerability of ABL503, and to Determine the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) of ABL503 in Subjects with Any Progressive Locally Advanced or Metastatic Solid Tumors

Study ID: NCT04762641
Start Date: 2021-04-01
End Date: 2026-06-15
Study Type

Interventional

Study Phase

Phase1

No. of Participants

100

Intervention / Treatment

ABL503

Sponsor

ABL Bio, Inc.

Source: clinicaltrials.gov

Share:
Add to list